P53 as an Adverse Prognostic Factor in Patients with Uterine Sarcoma: A Retrospective Study of 113 Patients

Authors

  • Yun Zhou Department of Gynecology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R., China
  • Lin-Jing Yuan Department of Gynecology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R., China
  • Ying Xiong Department of Gynecology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R., China
  • Xin Huang Department of Gynecology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R., China
  • Jia-xin Lin Department of Gynecology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R., China
  • Min Zheng Department of Gynecology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R., China

Keywords:

Uterine sarcoma, Immunohistochemistry, Independent prognostic factors, p53 over expression, Survival

Abstract

Objective: objective.Uterine sarcoma is an aggressive malignancy with poor prognosis. This study aimed to identify prognostic factors for this rare cancer.

Methods: A retrospective study involved 113 patients with uterine sarcomas was performed, including 61 cases identified by systematic computer-based searches of the literature and 52 patients diagnosed with uterine sarcomas at the SYSUCC. Immunohistochemical analyses of p53, p27, CD146 and Ki-67 were performed in tissue samples collected from the 52 patients in this institution, and for p53 in 45 cases from the literature.

Results: Median survival was 30.7 months for all 113 patients . The 5-year overall survival (OS) and disease-free survival (DFS) rates were 44% and 46%, respectively. Patient age, disease stage, histological type, tumor size and p53 were significant prognostic indicators for survival. Positive expression of p53 was significantly correlated with adverse OS, FIGO stage, premenopause, age <50 years, tumor size >5 cm, negative lymph node metastasis and negative expressions of p27 and CD146. Cox regression analysis showed that FIGO stage and p53 were independent prognostic factors for OS and DFS.

Conclusions: Our results indicated that P53 is a potential, novel prognostic marker for patients with uterine sarcoma and serves to guide treatment strategies.

References

1. Zaloudek C, Norris HJ. Mesenchymal tumors of the uterus. Blaustein’s Patholog of the Female Genital Tract. 1987; pp. 373–408.

2. Zaloudek C, Norris HJ. Malignant tumors of the uterus. Ther Umsch. 2007; 64(7):381-388.

3. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. The Lancet Oncology. 2009; 10(12):1188-1198.

4. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Onco-logica. 2012; 51(6):694-705.

5. Gadducci A. Prognostic factors in uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011; 25:783–795.

6. Vogelstein B, kinzler kw. P53 Function and dysfunction. Cell. 1992; 70:523-526.

7. Kirsch DG, Kastan MB. Tumor-suppressor p53 implica-tions for tumor development and prognosis. Journal of clin-ical oncology. 1998; 16(9): 3158-3168.

8. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H and Maehara Y. Overexpression of Hypoxia-Inducible Fac-tor 1α and p53 is a Marker for an Unfavorable Prognosis in Gastric Cancer. Clin Cancer Res. 2006; 12:5112.

9. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer. Clin Cancer Res. 2004;10:6215-6521.

10. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicator in Stage II Co-lon Cancer A Tissue Microarray Study. Clin Cancer Res. 2004; 10:3069.

11. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer. J Clin On-col. 2007; 25(33): 5240-5247.

12. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis. Mod Pathol. 2003;16(6):574–583.

13. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. P53 Expression in neoplasms of the uterine corpus. Am J Clin Pathol. 1992; 98(1):81-87.

14. Niemann TH, Raab SS, Lenel JC, Rodgers JR, Robinson RA. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol. 1995; 26(4):375-379.

15. He L, Li JD, Xiong Y, et al. Clinicopathological and molecu-lar markers associated with prognosis and treatment effec-tiveness of endometrial stromal sarcoma: a retrospective study in China. Arch Gynecol Obstet. 2013 Aug 20.

16. Zheng M, Tang L, Huang L, et al. Overexpression of kary-opherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol. 2010; 116(4): 884–891.

17. Kim SH, Kim JW, Kim YT, Kim JH, Yoon BS, Ryu HS. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. Int J Gynaecol Obstet. 2006; 95(3):272-277.

18. Major FJ, Blessing JA, Silverberg SG, et al. Gynecologic Oncology Group study. Prognostic factors in early-stage uterine sarcoma. Cancer. 1993; 71:1702–1709.

19. Goff BA, Rice LW, Fleischhacker D, et al. Uterine LMS and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993; 50:105–109.

20. Marchese MJ, Liskow AS, Crum CP, McCaffrey RM, Frick HC 2nd. Uterine sarcomas: A clinicopathologic study, 1965–1981. Gynecol Oncol. 1984; 18: 299–304.

21. Major FJ, Blessing JA, Silverberg SG, et al. Gynecologic Oncology Group study. Prognostic factors in early-stage uterine sarcoma. Cancer. 1993;71:1702–1709.

22. Babib A, Vongtoma V, Kurohara S, Webster J. Radiothera-py in the treatment of sarcomas of the corpus uteri. Cancer. 1969; 24:724–729.

23. Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhomme C. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validat-ed for soft tissue sarcoma. Cancer. 2000;88:1425– 1431.

24. Chauveinc L, Deniaud E, Plancher C, et al. Uterine sarco-mas: the Curie institute experience: prognosis factors and adjuvant treatments. Gynecol Oncol. 1999; 72:232–237.

25. Reichardt P. The treatment of uterine sarcomas. Ann On-col. 2012; 23 Suppl 10:x151-157.

26. Gaddducci A, Sartori E, Landoni F, et al. The prognostic relevance of histological type in uterine sarcomas: a Coop-eration Task Force (CTF) multivariate analysis of 249 cas-es. Eur J Gynecol Oncol. 2002; 23:295-299.

27. Bur ME, Periman C, Edelman L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol. 1992; 98:81-87.

28. Kohler MF, Berchuk A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992; 52:1622-1627.

29. Ambros RA, Vigna PA, Figge J, et al. Observations on tu-mor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer. 1994; 73:1686-1692.

30. Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 overexpression in endometrial can-cer. Int J Cancer. 1994;58:14-19.

31. Ambros RA, Sheehan CE, Kallakury BVS, et al. MDM2 and p53 protein expression in the subtypes of endometrial car-cinoma. Mol Pathol. 1996; 9:1165-1169.

32. Ben ShemE, Fintsi Y, Avinoach I, Glezerman M, Menczer J. p53 expression in tissue adjacent to endometrial carci-noma. Eur J Gynecol Oncol. 2002; 23:548-550.

33. Cherchi PL, Marras V, Capobianco G, et al. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcino-ma. Eur J Gynecol Oncol. 2001; 22:451-453.

34. Ohkouchi T, Sakuragi N, Watari H, et al. Prognostic signif-icance of Bcl-2, p53, overexpression and lymph node me-tastasis in surgically staged endometrial carcinoma. Am J Obstet Gynecol. 2002;187:353-359.

35. Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999;18(1):20 –28.

Downloads

Published

2014-01-01

How to Cite

Yun Zhou, Lin-Jing Yuan, Ying Xiong, Xin Huang, Jia-xin Lin, & Min Zheng. (2014). P53 as an Adverse Prognostic Factor in Patients with Uterine Sarcoma: A Retrospective Study of 113 Patients . International Journal of Medical Research, 2(01), 1–8. Retrieved from https://ijmrinternational.in/index.php/ijmr/article/view/34

Issue

Vol. 2 No. 01 (2014)

Section

Original Research Articles

License

The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.